Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Continuous ART Clear all
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients

NCT01399489
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension, Diabetes
Interventions
Exercise training
Behavioral
Lead sponsor
Springfield College
Other
Eligibility
35 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 9, 2026, 5:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Microbiome Non-invasive Diagnosis Tool

NCT03330444
View directory record Official record
Conditions
Infertility of Uterine Origin
Interventions
Endometrial biopsy and endometrial fluid collection
Procedure
Lead sponsor
Igenomix
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Norwalk, Connecticut • Margate, Florida • Chesterfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity

NCT02060279
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Lifestyle intervention and carotenoid supplements, Lifestyle intervention and placebo
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz

NCT00001758
View directory record Official record
Conditions
HIV Infection
Interventions
Abacavir, Amprenavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 5:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 9, 2026, 5:41 AM EDT
Not listed Phase 2Phase 3 Interventional

Impact of Metformin on Immuno-virologic Parameters in HIV

NCT04500678
View directory record Official record
Conditions
HIV/AIDS
Interventions
Metformin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 9, 2026, 5:41 AM EDT
Completed No phase listed Observational

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

NCT00385632
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral Regimens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
67
States / cities
Fresno, California • Mill Valley, California • Oakland, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 9, 2026, 5:41 AM EDT
Suspended Phase 1 Interventional

The DART DELIVER-02 Study

NCT07217379
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
MGD020, MGD014, Vorinostat, Temporary treatment interruption
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Grappling With Trauma: Brazilian Jiu-Jitsu for First Responders

NCT07783516
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD), Trauma and Stress Related Disorders, Occupational Stress, Emotional Regulation Difficulties, Anger Problems, Relational Problems, Irritability
Interventions
Brazilian Jiu-Jitsu Program
Behavioral
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Recruiting No phase listed Observational

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

NCT04979728
View directory record Official record
Conditions
HIV Treatment, HIV Prevention
Interventions
At Home Self-Collections
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Withdrawn Not applicable Interventional

Music as a Perioperative Therapy in Breast Cancer Patients

NCT03511079
View directory record Official record
Conditions
Breast Cancer
Interventions
Music
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 9, 2026, 5:41 AM EDT
Withdrawn Phase 2 Interventional

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

NCT03549689
View directory record Official record
Conditions
HIV/AIDS, HIV-1-infection, Osteopenia
Interventions
Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen
Drug
Lead sponsor
Philip Grant
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Testing State of the Art Remote Glucose Monitoring at Diabetes Camp

NCT01680653
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mini-glucagon, Remote monitoring, Carbohydrates
Drug · Device · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

NCT01568892
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
25
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 9, 2026, 5:41 AM EDT
Active, not recruiting Not applicable Interventional

Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy

NCT05283200
View directory record Official record
Conditions
Lifestyle
Interventions
Yoga, Cognitive Behavioral Therapy, Music
Behavioral
Lead sponsor
Imad Najm MD
Other
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Withdrawn Phase 2 Interventional

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

NCT05582694
View directory record Official record
Conditions
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Interventions
UB-421
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Development and Effectiveness of Museum-Based Experiences for Individuals With Chronic Pain

NCT04091893
View directory record Official record
Conditions
Chronic Pain
Interventions
Usual care/wait list, Art Rx, Artful Meditation
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

NCT00960622
View directory record Official record
Conditions
HIV
Interventions
Truvada, Combivir, Trizivir
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Positive Steps to Enhance Problem Solving Skills

NCT03092531
View directory record Official record
Conditions
Adherence
Interventions
Positive STEPS
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
16 Years to 29 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 9, 2026, 5:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

NCT03635788
View directory record Official record
Conditions
HIV Infections
Interventions
Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 9, 2026, 5:41 AM EDT